Stemline Therapeutics, Inc.
STML
STML was delisted on the 9th of June, 2020.
94 hedge funds and large institutions have $194M invested in Stemline Therapeutics, Inc. in 2020 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 36 increasing their positions, 25 reducing their positions, and 20 closing their positions.
44% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 25
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5% less funds holding
Funds holding: 99 → 94 (-5)
15% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 20
57% less capital invested
Capital invested by funds: $449M → $194M (-$255M)
79% less call options, than puts
Call options by funds: $80K | Put options by funds: $388K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Clearline Capital
New York
|
+$6.92M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
+$6.06M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$5.75M |
| 4 |
Goldman Sachs
New York
|
+$3.58M |
| 5 |
ELI
Empire Life Investments
Toronto,
Ontario, Canada
|
+$2.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$11.7M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$10.9M |
| 3 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
-$10.3M |
| 4 |
Axa
Paris,
France
|
-$6.2M |
| 5 |
PC
Polar Capital
London,
United Kingdom
|
-$4.43M |
STML Hedge Fund Activity: Q1 2020 in Review
94 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q1 2020, worth a combined $194M — down 57% from $449M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of STML and 17 opened new positions — a net loss of 3 holders — while 25 trimmed existing stakes and 36 added.
The largest buyer was Clearline Capital, adding an estimated $6.92M. The largest seller was AllianceBernstein, cutting an estimated $11.7M.
- 94 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q1 2020, down from 99 in Q4 2019.
- Funds reported $194M of Stemline Therapeutics, Inc. stock for Q1 2020, down 57% quarter-over-quarter.
- 17 funds opened new Stemline Therapeutics, Inc. positions in Q1 2020 and 20 closed out, a net change of -3 holders.
- The largest Stemline Therapeutics, Inc. buyer in Q1 2020 was Clearline Capital, an estimated $6.92M added.
- The largest Stemline Therapeutics, Inc. seller in Q1 2020 was AllianceBernstein, an estimated $11.7M sold.
Based on aggregated 13F filings for Q1 2020.